Effect of therapeutic Plasma exchange on Itraconazole Pharmacokinetics: a case study
Date
2022
Authors
Seah, V.
Sreeharan, T.
Kocic, D.
Reuter, S.E.
Girgis, L.
Marriott, D.J.E.
Stocker, S.L.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Therapeutic Drug Monitoring, 2022; 45(2):129-132
Statement of Responsibility
Conference Name
Abstract
The authors present the case of a 34-year-old male patient who underwent therapeutic plasma exchange (TPE) for amyopathic dermatomyositis. Immunosuppression resulted in Aspergillus lentulus pulmonary infection, requiring treatment with super bioavailable-itraconazole. Therapeutic itraconazole concentrations were attained after 2 weeks of treatment after dose adjustments. Interestingly, a substantial reduction in plasma itraconazole concentration was observed during TPE, which was attributed to an insufficient delay between the dosing of itraconazole and TPE initiation. Furthermore, there was an increase in plasma concentration post-TPE, which presumably reflects the redistribution of itraconazole from peripheral compartments back into plasma. This was confirmed by sampling of the TPE plasmapheresate, which revealed that changes in plasma concentration overestimated itraconazole clearance. These findings highlight that the pharmacokinetics of itraconazole are altered during TPE, which should be considered when timing drug administration and obtaining plasma concentrations.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2022 Wolters Kluwer Health